Humanitarian Device Exemption (Dystonia IRB)

This treatment has been approved for sale to the public.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00580658

First Posted: December 27, 2007

Last Update Posted: May 13, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Peter Konrad, Vanderbilt University

Purpose

The purpose of this study is to allow patients to undergo deep brain stimulation (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a requirement by the FDA for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. Thus, this proposal request authorization by the IRB to allow patients at VUMC to access this HUD therapy.

Condition	Intervention
Dystonia	Device: Medtronic Activa Gpi


Study Type:	Expanded Access What is Expanded Access?
Official Title:	Humanitarian Device Exemption for Medtronic Activa Dystonia Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: dopa-responsive dystonia early-onset primary dystonia

MedlinePlus related topics: Dystonia

U.S. FDA Resources

Further study details as provided by Peter Konrad, Vanderbilt University:


Study Start Date:	May 2006
Estimated Study Completion Date:	May 2020

Intervention Details:

Activa Therapy, Gpi

Other Names:

DBS
Gpi
Activa Therapy

Detailed Description:

The purpose of this IRB approved study is to allow patients to undergo deep brain stimulation (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a requirement by the FDA for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. Thus, this proposal request authorization by the IRB to allow patients at VUMC to access this HUD therapy.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	7 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients whose ages are in the range of 7 and 99 years old
Patients who are diagnosed with chronic, intractable (drug refractory)primary dystonia, including generalized and or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)as determined by a neurologist or neurosurgeon.
Patients who have failed appropriate medical therapy as determined by the SMD conference

Exclusion Criteria:

Patients younger than 7 years old
Patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist.
Patients who have not had an adequate trial of medical or non-surgical therapy as determined by the SMD conference.
Patients not deemed good candidates by the SMD conference group.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580658

Locations


United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

Vanderbilt University

Investigators


Principal Investigator:	Peter E Konrad, MD, Ph.D.	Vanderbilt University, Dept. Neurosurgery
Principal Investigator:	Hong Yu, MD	Vanderbilt University, Dept. Neurosurgery
Principal Investigator:	Thomas L Davis, MD	Vanderbilt University, Dept. Neurology
Principal Investigator:	John Y Fang, MD	Vanderbilt University, Dept. Neurology

More Information


Responsible Party:	Peter Konrad, Professor, Director of Functional Neurosurgery, Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00580658 History of Changes
Other Study ID Numbers:	060155
First Submitted:	December 13, 2007
First Posted:	December 27, 2007
Last Update Posted:	May 13, 2016
Last Verified:	May 2016

Keywords provided by Peter Konrad, Vanderbilt University:


Dystonia

Additional relevant MeSH terms:


Dystonia Dystonic Disorders Dyskinesias Neurologic Manifestations	Nervous System Diseases Signs and Symptoms Movement Disorders Central Nervous System Diseases

To Top